“Immune Hemolytic Anemia in Patients with Lymphoid Malignancy in Tanzania”

doi:10.21203/rs.3.rs-1446629/v1

Download PDF

Research Article

“Immune Hemolytic Anemia in Patients with Lymphoid Malignancy in Tanzania”

https://doi.org/10.21203/rs.3.rs-1446629/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this older preprint version

Read the latest preprint version →

Background

Hematological malignancies of the lymphoid lineage such as multiple myeloma, lymphomas and lymphoid leukemia are a burden to the world especially in Tanzania; anaemia is one of the presenting symptoms of these conditions and is found in almost 100% of the patients at diagnosis. Of particular importance Immune Hemolytic Anemia (IHA) which has a poor response to treatment and subsequently poor prognosis when it is associated with lymphoid malignancies. The aim of this study is to determine the magnitude of immune hemolytic anemia in lymphoid malignancies in Tanzania

Methods

This was a cross sectional study that recruited 86 patients with lymphoid malignancies attending both Ocean Road Cancer Institute (ORCI) and Muhimbili National Hospital (MNH). The clinical features were captured using a well-structured questionnaire. Laboratory results for Full Blood Count (FBC), reticulocytes count, total, indirect and direct bilirubin and Lactate Dehydrogenase (LDH) were retrieved from the laboratory reporting system. Additionally, a blood sample for the Direct Antiglobulin Test (DAT) was taken from all participants. This test was performed at the Central Pathology Laboratory (CPL) of MNH. Data analysis was performed using Statistical Package for the Social Sciences (SPSS 20.0) and Microsoft excel 2010. Data analysis was performed using South Texas Art Therapy Association (STATA 15.0).

Results

IHA, indicated by a positive DAT, was found in 10% of patients with lymphoid malignancies. Analysis of DAT among patients never exposed to chemotherapy showed a prevalence of 22%. Among 9 IHA cases, 2 were CLL (Chronic Lymphoid Leukaemia), 2 were MM (Multiple Myeloma), 3 was NHL (Non-Hodgkin Lymphoma), 1 was HL (Hodgkin Lymphoma) and 1 SLL (Small Lymphocytic Lymphoma). All 9 cases had decompensated hemolytic anemia.

Conclusion

IHA is a real complication of chronic lymphoid malignancies and DAT should be included in tests done during the course of management.

immune hemolytic anemia (IHA)

autoimmune hemolytic anemia (AIHA)

lymphoid malignancies

Tanzania

Cancer is a common health threat all over the world; According to the WHO, cancer is one of the leading causes of morbidity and mortality worldwide; In 2018, there were approximately 9.6 millions deaths with about one in every six people dying from cancer related causes; In 2014, there were approximately 21,000 reported deaths from cancer in Tanzania and 35,000 new diagnosis across all ages (1).

Immune phenomena are a well-known complication of hematological malignancies, and especially of those involving the lymphoid system. Indeed, three immune hematologic conditions associated with hematological malignancy are immune hemolytic anemia, idiopathic thrombocytopenic purpura and pure red cell aplasia: of these, immune hemolytic anemia is the most common, and it is more common in chronic hematological malignancy (2). Immune hemolytic anemia can be classified as (i) auto-immune hemolytic anemia (AIHA) that is the most commonly associated with hematological malignancies; (ii) allo-immune hemolytic anemia as a consequence of blood transfusion that is common practice among hematological malignancy (3); (iii) drug induced hemolytic anemia. IHA is also classified as primary, or idiopathic, when thereis no associated condition; or secondary when an underlying disorder can be identified: the latter is estimated to be about one-half of all cases of AIHA. Hematological malignancy is thought to be the number one cause of the secondary type (4). However, patients with ‘primary’ AIHA may be seen to develop subsequently NHL, multiple myeloma, CLL or other lymphoid malignancies (5).

The Direct Antiglobulin Test (DAT) in the diagnostic test for IHA, but it is not routinely carried out in most hospitals in Tanzania (6). Anemia is one of the commonest symptoms of hematological malignancy and very frequently causes the patient to seek medical attention even before the cancer is diagnosed. Proper management of anaemia depends on the cause of anaemia and can significantly improve the quality of life (6) (7).

The aim of this study is to determine the magnitude of IHA in B cell lineage malignancies in Tanzania.

This was a descriptive cross-sectional hospital-based study on patients with hematological malignancies attended in the two major cancer referral hospitals (Muhimbili National Hospital and Ocean Road Cancer Institute) in Tanzania from November 2019 to March 2020. These hospitals serve the whole country, with patients being transferred from regional hospital or through direct consultations. Approximately 96 patients with lymphoma and 45 patients with other chronic hematological malignancies are attended in both hospitals per year.

The study population consisted of patients with chronic lymphoid malignancies attended at MNH and ORCI from November 2019 to March, 2020. The minimum sample size required was calculated using one group proportion formula. The prevalence rate computed in this formula was 5.6% which was from a previous study done in Nigeria (7). Therefore, minimum projected sample size was 86. All patients with chronic lymphoid malignancies (Multiple myeloma, lymphomas and chronic lymphocytic leukaemia) aged 18 and above were eligible to participate in the study. Patients with acute lymphoblastic leukaemia and those known to have IHA were excluded from the study.

A well-structured questionnaire was used to capture the information on age, sex, reason of admission/consultation, history of transfusion, symptoms of anemia, and examination findings such as paleness, jaundice, splenomegaly, lymphadenopathies, hepatomegaly and treatment were assessed. Diagnosis of a lymphoid malignancy was confirmed from peripheral blood smear, bone marrow, serum electrophoresis and lymphnode biopsy results documented in the patients’ records. Results for Full Blood Count (FBC), reticulocytes count, total, indirect and direct bilirubin and Lactate Dehydrogenase (LDH) were retrieved from the patients’ records. DAT was performed at the CPL in MNH

We received ethical approval from the MUHAS institutional review board and permission to conduct the study from the hospital administration of ORCI and MNH.

The total of 94 patients with lymphoid malignancies consulted MNH and ORCI during our study period. Seven patients were excluded from the study because they had no hemolytic markers results in the hospital reporting system and one excluded because of failure to consult for participating in the study. We therefore enrolled 86 participants.

4.1 Demographic and baseline characteristics

The majority (80%) of the participants were enrolled from MNH (69/86); 58% (50/86) were male, and the mean age of participants was 56 years (56 ± 16). With regards to diagnosis, 42% (36/86) had lymphoma, 34% (29/86) had multiple myeloma, and 24% had CLL. (Table 1)

Table 1

Demographic and baseline characteristics of patients with lymphoid malignancy
Characteristic	Lymphoid malignancies: N = 86	Percentage
Age, Mean ± SD	56 ± 16
Gender
Female	36	42
Male,	50	58
Hospital where treated
ORCI	17	18
MNH,	69	80
Diagnosis
CLL	21	24
Multiple myeloma	29	34
Lymphomas	36	42
PS + BMB: peripheral smear plus bone marrow biopsy; N or n: number of participants; SPE: serum protein electrophoresis, MNH: Muhimbili National Hospitals; ORCI: Ocean Road Cancer Institute

4.2 Clinical Presentation of participants

The most common symptom was fatigue related to anemia that was manifested followed by other symptoms of anemia such as palpitations, dizziness, headache. The history of transfusion with blood products and time from last transfusion was assessed, 62% (53/86) of the patients had a history of blood transfusion at some point in their life time, with most common blood product being packed red cells (52/53). For these participants with a transfusion history, 53% (28/53) reported to have received the transfusion more than three months prior the time we collected blood sample for DAT. 64% (56/86) of patients had been on steroids (55 was on chemotherapy containing steroids and one on steroids alone). (Table 2)

Table 2

Clinical information of participants
Characteristic	Lymphoid malignancies: N = 86	Percentage
Symptoms
Fatigue score/10, Median (IQR)	4 (1–5)
Palpitations	19	22
Dizziness	24	28
Headache	32	37
Signs
Pallor Moderate	15	17
Mild	20	23
No pallor	24	28
Severe	27	31
With hepatomegaly	6	7
With jaundice	12	14
With Splenomegaly	29	34
With Lymphadenopathy	35	41
Transfusion history in life	53	62
Blood product
PRBCSs + Platelets	1	1
PRBCs	52	61
Number of units of transfusion, Median (IQR)	4 (0–6)
0–72 hours	4	5
3-120 days	21	24
> 120 days	28	33
On Steroids	56	65
Time on Chemotherapy in months, Median (IQR)	3 (0–7)
FBC: Full Blood Count, PRBC_S: Packed red blood cells, IQR: Interquartile range

FBC was done to assess the level of anemia. The median hemoglobin level was 8.8 (6.2–10.5) in the lymphoid malignancies.

4.3 Prevalence of IHA in lymphoid malignancies

Nine patients were found to have positive DAT making the prevalence of IHA among lymphoid malignancies 10% (9/86).

4.4 Frequency of IHA in individual sub-types of lymphoid malignancies

Frequency of IHA was highest in lymphoma, where it was 14% (5/36). Multiple myeloma had 7% (2/29) and CLL had 9% (2/21). (Table 3)

Table 3

Frequency of IHA in different sub-types of lymphoid malignancies
Type of lymphoid malignancies	IHA Positive N = 9	IHA Negative N = 77 (%)	Total N = 86
Lymphomas, n (%)	5 (14)	31(86)	36
NHL, n (%)	3 (16)	16 (84)	19
HL, n (%)	1 (14)	6 (86)	7
SLL, n (%)	1 (50)	1 (50)	2
MCL, n (%)	0 (0)	5 (100)	5
Splenic lymphoma, n (%)	0 (0)	2 (100)	2
Cutaneous Lymphoma, n (%) Multiple myeloma, n (%) CLL, n (%)	0 (0) 2 (7) 2 (9)	1 (100) 27 (93) 19 (91)	1 29 21
CLL: chronic lymphocytic leukemia, NHL: Non-Hodgkin lymphoma, HL: Hodgkin lymphoma, MCL: mantle cell lymphoma, SLL: small lymphocytic lymphoma

4.5 Compensated versus de-compensated hemolytic anemia (N = 9)

Among 9 participants who were found to have immune hemolytic anemia, all had decompensated anemia; the lowest Hemoglobin was 5.1 g/dl and the highest one was 9.8 g/dl.

4.5 Treatment history and transfusion history in patients with IHA

As summarized in Table 4, among 9 participants with IHA, two patients were on steroids (one patient was on steroid alone and one was on chemotherapy containing steroid). The odd ratio of being on steroids versus not on steroids was found to be 8.2 with 95% confidence interval of 1.6–42.5. Therefore, the risk of developing IHA while not on steroids was 8.2 times more compared to if on steroids.

Table 4

IHA in relation to chemotherapy and blood transfusion
Parameter	IHA Positive N = 9	IHA Negative N = 77	p-value	Odds ratio (95% CI)
Types of malignancy not on steroids, n (%)	7 (23)	23 (77)
Multiple myeloma	2 (20)	8 (80)
CLL	1 (20)	4 (80)
Lymphomas	4 (27)	11 (73)
Steroids			0.008
On steroids, n (%)	2 (4)	54 (96)
Not on steroids Not on steroids Vs on steroids	7 (23)	23 (77)		8.2 (1.6–42.5)
Transfusion history in life			0.295
Has been transfused, n (%)	4 (8)	49 (92)
Never transfused, Transfused Vs Never transfused	5 (15)	28 (85)		0.46 (0.11–1.84)
Time from the last transfusion Never transfused	5 (15)	28 (85)	0.295
> 120 days, n (%)	1 (4)	27 (96)
3-120 days, n (%)	1(25)	3(75)
0–3 days, n (%)	2 (10)	18 (90)
OR: odds ratio

3.6 IHA and hemolytic markers

Apart from hemoglobin and reticulocyte count, the hemolytic markers were significantly higher in patients with IHA compared to those without IHA. (Table 5)

Table 5

Laboratory findings in patients with lymphoid malignancies with and without IHA
Parameter	IHA positive, N = 9	IHA negative, N = 77	p-value
Hemoglobin: n = 86, (Mean ± SD)	6.85 ± 1.48	8 ± 2.57	0.054
Reticulocytes: n = 86 Median (IQR)	80700 (45200–99000)	41600 (23800–55800)	0.0814
Total Bilirubin Median (IQR)	34.9 (30.9–62.5)	10.5 (6.8–15.6)	< 0.0001
Direct Bilirubin Median (IQR)	10.9 (8-15.4)	4.3 (3-7.5)	0.0017
Indirect Bilirubin Median (IQR)	24 (15.5–54.1)	5.5(3.9–8.1)	< 0.00001
LDH Median (IQR)	516 (324–867)	293 (222–432)	0.0062

In this cross-sectional study, we have established the prevalence of immune hemolytic anemia among our patients with lymphoid malignancies: specifically CLL, MM and lymphomas.

5.1 Prevalence of immune hemolytic anemia among lymphoid malignancy

The prevalence of immune hemolytic anemia among lymphoid malignancies was 10%. Almost the same percentage was reported in the study done in India by Ghosh et al where the prevalence was 10.6% (28). Thus, patients with lymphoid malignancy must be regarded as being at a higher risk of developing IHA, as from a review article on causes of anemia in cancer by Balana Louis Gaspar et al (27). A study done in south Nigeria by Kaladada et al showed a prevalence of AIHA of about 6% (2/35) among B cell neoplasm; this lower might be explained by the fact that most of their participants were already on chemotherapy, and all those with positive DAT were not on chemotherapy(7). In our study, we observed 4 out of 9 patients with positive DAT had never been transfused in life and one had been transfused in more than 120 days ago; That means the prevalence of AIHA in our study can be estimated to be 6% (5/86) that is almost the same in the study of south Nigeria(7).

5.2 Frequency of IHA among different types of B cell neoplasms

The prevalence of IHA among CLL/SLL, Multiple myeloma, NHL and HL was 13% (3/23), 7% (2/29), 13.8% (4/29) and 14% (1/7) respectively. Almost the same prevalence among CLL/SLL was reported in the study done in Egypt by Basma et al that showed the prevalence of AIHA in CLL to be 11.9% (10). Some studies reported prognostic implication of lymphoid malignancies when presented with IHA (11)(12)(13).

We have low prevalence of IHA among multiple myeloma compared to other few published studies. The study done by Rajesh et al in India showed a slightly higher prevalence of 10.6% (14) that is different from ours that is 7%; this difference can be explained by the fact that most of our participants were already on chemotherapy containing steroids that may have reduced the frequency of IHA.

So far, there are very few studies done showing prevalence of IHA in lymphomas. A study done by Ji Cheng in China showed a prevalence of AIHA among NHL of 0.91%, which is significantly lower than the present study that showed a prevalence of 14% (1/7). Similarly, the present study reports prevalence of 14% for HL but other studies reported that IHA is rare among HL. However, our sample size for lymphomas was small and also our patients present at late stage of the disease which is a risk factor of developing AIHA in hematological malignancy as explained by Ji Cheng et al (15). The same as others wherever these conditions develop AIHA, the prognosis is poor (16)(17) but our study did not assess the survival rate as it was cross sectional study.

5.3 Association between IHA and treatment offered to patients with chronic lymphoid malignancies.

The prevalence of IHA among participants who had never been exposed to chemotherapy or steroids was 23% (7/31). Among 9 participants with positive DAT, 78% (7/9) had never been on steroids whereas 22% (2/9) had been on the latter: this difference was statistically significant with P value of 0.012 and this showed that steroids may be protective to develop IHA. The observed odds ratio was 8.2 that means the risk of developing IHA while not on steroids is 8.2 times more if you are on steroids. This can be explained by the fact that first line and most effective treatment of IHA is steroids and almost all chemotherapy regimen for lymphoid malignancies include steroids, so there is much chance that if the participant had IHA but was on steroids, the disease will clear out and hence negative DAT (18).

4 out 9 positive DAT meaning 44% (4/9) had been transfused in less than 120 days that is the life span of red cells; this means that they may have allo-immune hemolytic anemia or AIHA.

5.4 Status of different hemolytic markers

DAT is the gold standard for the diagnosis of AIHA; but other parameters help to assess the severity of hemolysis. These includes reticulocytes count, indirect bilirubin and LDH (19)(20) (21)(22); they may suggest AIHA even in the rare cases (estimated 5%) when DAT is negative (23). They are also very important in non-immune hemolytic anemia where they will raise whereas DAT is negative

In our study the median absolute reticulocytes count among IHA and non IHA was 80700/L and 41600/L: a considerable difference, though not statistically significant. The highest reticulocyte count that was reported among IHA patients was 557480/L was and lowest was 1380/L. Three out of nine participants had reticulocytes count below the low limit of reference range and two had the one higher than the upper limit of reference range, four remaining had the one within the limits of normal range that is 50,000-100,000/L. Therefore, reticulocytopenia with IHA was found in 33.3% (3/9). This findings is similar in other studies where cases of AIHA with reticulocytopenia have been reported like Lockard et al reported four cases of AIHA and reticulocytopenia with erythroid hyperplasia in the bone marrow (24); the same findings were reported by William et al who assessed 55 cases of AIHA and he found 14 (25.5%) of them had reticulocytopenia and they had poor prognosis compared to those with normal or higher reticulocytes count(25).

In our study, we have found that total, conjugated, unconjugated bilirubins were higher in IHA group compared to non IHA and the difference was statistically significant. These findings may suggest that total and indirect bilirubin can be a good marker of IHA for treatment in case DAT is not available, however, more studies are required to confirm this concept. Jorge et al reported a case of high indirect bilirubin in hemolysis (26).

LDH was high in both IHA and non IHA groups but higher in IHA with a median of 516 and 293 respectively and a P value of 0.0062. LDH usually rises in case of malignancies (27) and it has been used for long time as treatment response monitoring for lymphomas, the lower value observed in the non IHA group should be due to the fact that most of them were on chemotherapy for long period of time. LDH has been used for long time as a marker of hemolysis especially intravascular hemolysis (28) and our study can show how it is even relevant in extravascular hemolysis.

To our knowledge, this is the first study in Tanzania, indeed in East Africa, exploring the association between immune hemolytic anemia and any type of haematological malignancy. We had a good sample size and in order to get a sufficiently large number of participants, thus increasing the power of our study, we needed a multi-center data collection (MNH and ORCI), that is also strength of our study. IHA specifically AIHA among lymphoid malignancies is a big concern, it has both clinical and prognostic implication. Its main presentation after symptoms of anemia, there is jaundice with possible splenomegaly. Indirect bilirubin and LDH raises; and DAT will be positive.

Our study has found that the prevalence of IHA among chronic lymphoid malignancy including those on and off chemotherapy is 10%. This means that among 10 patients with chronic lymphoid malignancy who attend MNH and ORCI, one may have IHA. This is a big number to show that the magnitude of IHA among chronic lymphoid malignancy is not neglectable. Because of the short time for data collection, we couldn’t determine the prognosis for those with and without IHA; despite that most literatures we cited showed that those with IHA have poor prognosis compared with those without IHA.

AIHA Autoimmune Hemolytic Anemia

ALL Acute Lymphoblastic Leukemia

AML Acute Myeloid Leukemia

CLL Chronic Lymphocytic Leukemia

CML Chronic Myeloid Leukemia

DAT Direct Antiglobulin Test

FACT-F Functional Assessment of Cancer Therapy-Fatigue

FBP Full Blood Picture

HL Hodgkin lymphoma

IAT Indirect Antiglobulin Test

IHA Immune Hemolytic Anemia

LDH Lactate Dehydrogenase

MM Multiple Myeloma

NHL Non-Hodgkin Lymphoma

RBC Red Blood Cells

SOP Standard Operation Procedure

SPSS Statistical Package for the Social Sciences

STATA South Texas Art Therapy Association

WHO World Health Organization

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

It is attached. we have gotten ethics approval from the Muhimbili University of Health and Allied Sciences (MUHAS)

CONSENT FOR PUBLICATION

N/A. Our manuscript does not contain any individual person’s data in any form (including any individual details, images or videos)

AVAILABILITY OF DATA AND MATERIALS

Dataset will be available

COMPETING INTERESTS

We declare no conflict of interests.

FUNDING

This study was conducted as part of the corresponding author’s completion of master’s in medicine of hematology and blood transfusion at Muhimbili University of Health and Allied Sciences (MUHAS). He was funded by Government of Rwanda in all his studies including this research

AUTHORS’ CONTRIBUTIONS

The research protocol was prepared by the first author in close collaboration with the last author and second author. The first author collected, analyzed data under supervision of the last and second authors. Manuscript was prepared by the first author and corrected by all authors mentioned.

ACKNOWLEDGEMENTS

We wish to acknowledge the support of Muhimbili National Hospital/department of hematology and blood transfusion, Ocean Road Cancer Institute (ORCI) and the cooperativeness of the study participants.

Kohi TW, Essen L Von, Masika GM, Gottvall M, Dol J. Cancer-related concerns and needs among young adults and children on cancer treatment in Tanzania : a qualitative study. BMC Cancer. 2019;19(1):82.
Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia : clinical , therapeutic , and prognostic features. Blood. 2000;95(9):2786–92.
Ddungu H, Krantz EM, Kajja I, Naluzze S, Nabbanja H, Nalubwama F, et al. Transfusion Challenges in Patients with Hematological Malignancies in Sub-Saharan Africa: A Prospective Observational Study from the Uganda Cancer Institute. Sci Rep. 2020;10(1):1–9.
Catroux M, Masmouhi B El, Roblot P. Diagnostic et prise en charge de l’anémie hémolytique auto-immune à l’exclusion des formes secondaires à une cause néoplasique. Adéquation de la prise en charge au PNDS octobre 2009. La Rev Med interne. 2017;8(10):8.
Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. Guidelines on the management of drug-induced immune and secondary autoimmune , haemolytic anaemia. Br J Haematol. 2017;177(2):208–20.
Liebman HA, Weitz IC. Autoimmune Hemolytic Anemia. Med Clin NA. 2017;101(2):351–9.
Kaladada KI, Nwauche CA, Ejele OA. Autoimmune Hemolytic Anemia In Cancer Patients At a Tertiary Center In South Nigeria. Blood 122 4658. 2013;122(21):4658–4658.
Ghosh J, Rk S, Saxena R, Gupta R, Vivekanandan S, Sreenivas V, et al. Prevalence and aetiology of anaemia in lymphoid malignancies. Natl Med J India 2013;26(2)79‐81. 2013;26(2):79–81.
Gaspar BL, Sharma P, Das R, Gaspar BL, Sharma P, Das R. Anemia in malignancies : Pathogenetic and diagnostic considerations Anemia in malignancies : Pathogenetic and diagnostic considerations. Hematol 2015 Jan;20(1)18-25. 2015;20(1):18–25.
Atef B, Azmy E, Aladle D, Mabed M. The prevalence and prognostic significance of autoimmune cytopenias in a cohort of Egyptian patients with chronic lymphocytic leukemia. Hematol Oncol Stem Cell Ther. 2019;12(2):97–104.
Shvidel L, Tadmor T, Braester A, Bairey O. Pathogenesis , prevalence , and prognostic significance of cytopenias in chronic lymphocytic leukemia: a retrospective comparative study of 213 patients from a national CLL database of 1518 cases. 2013;661–7.
Kyasa MJ, Parrish RS, Schichman SA, Zent CS. Autoimmune Cytopenia Does Not Predict Poor Prognosis in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma. Am J Hematol. 2003;73(1):1–8.
Rogers KA, Woyach JA. Secondary autoimmune cytopenias in chronic lymphocytic leukemia. Semin Oncol. 2016;43(2):300–10.
Kashyap R, Singh A, Kumar P. Prevalence of autoimmune hemolytic anemia in multiple myeloma : A prospective study. Asia-Pac J Clin Oncol 2014. 2014;12(2):e319-22.
Zhou J, Wu M, Peng Z, Zhao W, Bai Z. Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia. Med. 2020;99(7):1-5 e19015.
Sallah S, Sigounas G, Vos P, Wan JY, Nguyen NP. Original article Autoimmune hemolytic anemia in patients with non-Hodgkin’s lymphoma : Characteristics and significance. Ann Oncol. 2000;11(12):1571–7.
Doni E, Carli G, Rocco A Di, Sassone M, Gandolfi S, Patti C, et al. Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease. Hematol Oncol. 2017;35(1):135–7.
Zanella A, Barcellini W, Ematologia UO, Irccs F, Granda C, Maggiore O. Review Treatment of autoimmune hemolytic anemias. Haematologica. 2013;99(10):1547–54.
Klinik M, Erlangen U, Abteilung T, Erlangen U. Hämolytische Anämien beim Erwachsenen Hemolytic anemias in adults. Dtsch Med Wochenschr. 2011;136(45):2308–12.
Barcellini W, Fattizzo B. Clinical Applications of Hemolytic Markers in Hemolytic Anemia. 2015;2015.
Packman CH. The Clinical Pictures of Autoimmune Hemolytic Anemia. Transfus Med Hemother. 2015;42(5):317–24.
Dhaliwal G, Cornett PA, Tierney LM. Hemolytic Anemia. 2004;2599–606.
Jaime-pérez JC, Salazar-cavazos L, Gómez-almaguer D. Evans syndrome : clinical perspectives , biological insights and treatment modalities. J Blood Med. 2018;9(10):171–84.
Conley CL, Scott M. Autoimmune Hemolytic Anemia With Reticulocytopenia. JAMA. 2015;244(7):15.
Crosby WH, Rappaport H. Reticulocytopenia in autoimmune hemolytic anemia. Blood (1956). 1956;11(10):929–36.
Maldonado JE, Kyle RA, Schoenfield LJ, Maldonado JE, Kyle RA, Schoenfield LJ. Increased Serum Conjugated Bilirubin in Hemolytic Anemia. Postgrad Med J. 2017;55(2):183–90.
Long G, Tang W, Fu X, Liu D, Zhang L, Hu G, et al. Pre-treatment Serum Lactate Dehydrogenase Predicts Distant Metastasis and Poor Survival in Nasopharyngeal Carcinoma. 2019;10.
Kato GJ, McGowan V, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis. Blood 2006;107(6):2279–2285. 2006;7.

No competing interests reported.

Download PDF

Version 1

posted

You are reading this older preprint version

Read the latest preprint version →

“Immune Hemolytic Anemia in Patients with Lymphoid Malignancy in Tanzania”

Status:

Version 1

Abstract

Background

Methods

Results

Conclusion

Figures

Background

Methods

Results

4.1 Demographic and baseline characteristics

4.2 Clinical Presentation of participants

4.3 Prevalence of IHA in lymphoid malignancies

4.4 Frequency of IHA in individual sub-types of lymphoid malignancies

4.5 Compensated versus de-compensated hemolytic anemia (N = 9)

4.5 Treatment history and transfusion history in patients with IHA

3.6 IHA and hemolytic markers

Discussion

5.1 Prevalence of immune hemolytic anemia among lymphoid malignancy

5.2 Frequency of IHA among different types of B cell neoplasms

5.3 Association between IHA and treatment offered to patients with chronic lymphoid malignancies.

5.4 Status of different hemolytic markers

Conclusion

Abreviations

Declarations

References

Additional Declarations

Status:

Version 1